1. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
- Author
-
Elfiky AA
- Subjects
- Adenosine Monophosphate chemistry, Adenosine Monophosphate metabolism, Alanine chemistry, Alanine metabolism, Alphacoronavirus enzymology, Alphacoronavirus genetics, Amino Acid Sequence, Antiviral Agents metabolism, Betacoronavirus genetics, COVID-19, Catalytic Domain, Computational Biology methods, Coronavirus Infections virology, Drug Repositioning methods, Guanosine Monophosphate chemistry, Guanosine Monophosphate metabolism, Guanosine Triphosphate chemistry, Guanosine Triphosphate metabolism, Humans, Molecular Docking Simulation, Pneumonia, Viral virology, Protein Binding, Protein Conformation, alpha-Helical, Protein Conformation, beta-Strand, Protein Interaction Domains and Motifs, RNA-Dependent RNA Polymerase chemistry, RNA-Dependent RNA Polymerase metabolism, Ribavirin metabolism, SARS-CoV-2, Sequence Alignment, Sequence Homology, Amino Acid, Sofosbuvir metabolism, Thermodynamics, Uridine Triphosphate chemistry, Uridine Triphosphate metabolism, Viral Proteins chemistry, Viral Proteins metabolism, COVID-19 Drug Treatment, Adenosine Monophosphate analogs & derivatives, Alanine analogs & derivatives, Antiviral Agents chemistry, Betacoronavirus enzymology, Coronavirus Infections drug therapy, Guanosine Monophosphate analogs & derivatives, Pneumonia, Viral drug therapy, RNA-Dependent RNA Polymerase antagonists & inhibitors, Ribavirin chemistry, Sofosbuvir chemistry, Viral Proteins antagonists & inhibitors
- Abstract
Aims: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp)., Materials and Methods: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin., Key Findings: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease., Significance: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection., Competing Interests: Declaration of competing interest The author declares that there is no competing interest in this work., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF